CD44 and neoplasm: There are limitations to the NP-ICG-HA multimodalimaging platform.Although CD44 is an exciting target and is overexpressed on breastcancer,26,57 as the tumor is highly heterogeneous, theremay be populations of cancer cells low in CD44 expression, which willescape the detection.